METABOLIC SYNDROME - AN EMERGING RISK FACTOR FOR CHRONIC KIDNEY DISEASE

Ashwini Shenai; Savitha G

doi:10.22159/ajpcr.2018.v11i6.24658

Authors

Ashwini Shenai Department of Biochemistry, Saveetha Dental College, Saveetha University, Chennai, Tamil Nadu, India.
Savitha G Department of Biochemistry, Saveetha Dental College, Saveetha University, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.24658

Keywords:

Metabolic Syndrome, Chronic Kidney Disease, Urea, Creatinine

Abstract

Objective: Metabolic syndrome (MetS) is a common health problem worldwide. According to third national health and nutrition examination survey criteria, about 47 million people have MetS. It is defined as having three or more of the following five risk factors including abdominal obesity, increased triglyceride levels, low-density lipoprotein cholesterol level, elevated blood pressure, and elevated fasting glucose levels. These components of MetS are major risk factors for the development of chronic kidney disease (CKD) also. CKD is a major public problem and it is a major risk factor for the development of cardiovascular disease. Hence, the aim of the current study was to evaluate the association between MetS and CKD.

Methods: A total of 50 patients reporting to Saveetha Dental College and Hospitals were enrolled into the study which includes 25 patients with MetS and 25 healthy individuals. 5 mL of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar (FBS), serum triglycerides, serum urea, and creatinine using the standard kit method. The data obtained were subjected to statistical analysis using the SPSS software.

Results: The mean body mass index, FBS, serum creatinine, and triglyceride levels were higher in MetS patients in comparison to healthy individuals. The mean body mass index (BMI), FBS, serum urea, serum creatinine, and triglyceride levels in the control group and MetS group were 27.75Â±3.67, 84.8Â±12.5, 17.52Â±5.2, 0.91Â±0.17, and 96.5Â±60.13 and 35.14Â±4.25, 108.8Â±34.69, 21.4Â±5.9, 1.0Â±0.14, and 239.76Â±51.21, respectively. There was a significant difference in the mean BMI, FBS, urea, creatinine, and triglyceride levels of the above group.

Conclusion: Serum urea and creatinine levels were significantly higher in MetS individuals. Hence, MetS could be a one of the risk factors for the development of CKD.

Downloads

Download data is not yet available.

Author Biography

Ashwini Shenai, Department of Biochemistry, Saveetha Dental College, Saveetha University, Chennai, Tamil Nadu, India.

1-Graduate Student, Bachelor of Dental Surgery

2- Senior Lecturer, Department of Biochemistry

References

Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014: Article ID: 943162.

Nerkar D, Mukherjee A, Metha BK, Banerjee S. Metabolic syndrome associated complications. Int J Pharm Pharm Sci 2015;7 Supple7:22-5.

Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.

Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systemic review of metabolic syndrome biomarkers: A panel for early detection,management, and risk stratification in west Virginian Population. Int J Med Sci 2016;13 Supple 1:25-38.

Lusis AJ, Attie AD, Reue K. Metabolic syndrome: From epidemiology to systems biology. Nat Rev Gen 2008;9:819-30.

Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med 2011;9:48.

Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol 2014;3:210-9.

Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006;17:S81-5.

Laguardia HA, Hamm LL, Chen J. The metabolic syndrome and risk of chronic kidney disease: Pathophysiology and intervention strategies. J Nutr Metab 2012;2012:652608.

Williams JD, Woods F. Insulin resistance, the metabolic syndrome and renal failure-is there a special problem for patients treated with peritoneal Dialysis. Eur Endocrinol 2006;2:1-5.

Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic nature of CKD. Nat Rev Nephrol 2017;13:344-58.

Zoccali C, Kramer A, Jager KJ. Chronic kidney disease and end-stage renal disease. A review produced to contribute to the report- the status of health in the European Union: Towards a healthier Europe. Clin Kidney J 2000;3 Supple 3:213-24.

Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med 2016;129:153-62.

Levin A. Identification of patients and risk factors in chronic kidney disease-Evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16 Suppl 7:57-60.

Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, NyrÃ©n O, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695-702.

Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:198-203.

Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD-What should Nephrologist Know? J Am Soc Nephrol 2013;24 Supple 11:1727-36.

Gopala A, Sharma VK, Ganti SS. Rosiglitazone-a journey that never completed. Int J Pharm Pharm Sci 2010;2 Suppl 2:7-9.

Kopple JD. Obesity and chronic kidney disease. J Ren Nutr 2010;20:S29-30.

Bhowmik D, Tiwari SC. Metabolic syndrome and chronic kidney disease. Indian J Nephrol 2008;18:1-4.

Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: A 5-year prospective analysis of the Hong Kong diabetes registry. Diabetes Care 2008;31:2357-61.